009420.KS
Hanall Biopharma Co.,Ltd
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 53,900.00
−2.00%Year over year
Reported trailing growth
- Revenue
- +8.4%
- EBITDA
- —
- EBIT
- +0.1%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -33.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +12.2%
- EBITDA
- -27.3%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +76.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026